Citigroup’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Citigroup’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-436,840	Closed	-$48.5K	–	6040
2022 Q4	$48.5K	Sell	436,840 -181,803	-29%	-$116K	﹤0.01%	4289
2022 Q3	$656K	Buy	+618,643	New	+$1.41M	﹤0.01%	3035
2021 Q3	–	Sell	-1	Closed	–	–	6456
2021 Q2	$0	Sell	1 -692	-100%	-$4.36K	﹤0.01%	6520
2021 Q1	$8K	Buy	+693	New	+$13.7K	﹤0.01%	5782

Other funds holding LHDX

Eclipse Ventures Palo Alto, California $2.57B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Citigroup's LHDX Position: Q1 2023 in Review

Citigroup sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 436,840 shares — an estimated $48.5K sold.

Citigroup first reported a position in LHDX in Q1 2021 and held it in 4 quarters. The position peaked at $656K in Q3 2022. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

Citigroup reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citigroup sold 436,840 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $48.5K.
Citigroup first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Citigroup's Lucira Health, Inc. Common Stock position peaked at $656K in Q3 2022.
6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.